About Cardiff Oncology, Inc. - Common Stock (CRDF)
Cardiff Oncology Inc is a biotechnology company focused on developing innovative cancer therapies aimed at treating solid tumors. The company is dedicated to uncovering new treatment options for patients through its proprietary drug candidates and advanced research platforms. By leveraging scientific expertise and clinical research, Cardiff Oncology aims to address significant unmet needs in oncology, with an emphasis on enhancing patient outcomes and quality of life. Through collaboration with healthcare professionals and ongoing clinical trials, the company strives to bring novel therapeutics to market and contribute to the evolving landscape of cancer treatment. Read More
NEW YORK, NY / ACCESS Newswire / December 9, 2025 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day Year-End Virtual Investor Conference taking place Wednesday and Thursday, December 10-11, 2025. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
– Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer –
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
